Grant Review (past 10 years):

2025: NIH ZRG1 CDPT Z08, ZRG1 CDPT-C (08) F, ACS, NIH Director’s Pioneer award (DP1)

2024: Hong Kong Research Grants Council, NIH ZGM1 RCB-X(C3), DoD LCRP, DoD AKCI

2023: Hong Kong Research Grants Council, DoD LCRP Con-IIT, NIH Human Immunology SEP

2022: NIH ZGM1 RCB-3 (C2), ZAI1 SB-1(J3), ZRG1 MBBC-G (50) R, P01, DoD AKCI-ECS

2022: Distinguished Research Award in Basic & Applied Sciences, University of Louisville 

2021: NCI (2/4/21), HMAI (6/24/21, 11/04/21), DoD LCRP IITRA panel (9/27/21)

2020: NIH HAMI (IMM-T57, 2/27, 6/25, 10/24/2020), NCI SPORE (9/24/20), Israel Science Foundation

2019: NIH P01 (2/6/2019), NIH Transformative Research Award (TRA) review panel, U54 (6/26/2019), Immunometabolism SEP (10/6/2019), DoD IMM panel (10/26/19)

2018: NIH/NCI SPORE (1/25), ZRG OTC-X (55, Feb 20), NCI SPORE (5/17/18, 7/2018), CII (10/18/18)

2017: NIH ZRG 1 OTC-X (55, May 3), TTT, ZRG1 OTC-X (55, June 30), ZRG1 OTC-K (02) M, NSFC

2016: FDA site visit reviewer and NIH ZRG1 BCMB-A, ZRG1 OCT-XX(55)

2015: Ad hoc NIH CII Study Section

2014, 2015: Grant Reviewer, National Psoriasis Foundation

2010-2014:  Regular member, NIH TTT Study Section

Editorial service:

2020-2029: Co-Editors-in-Chief, Translational Oncology

2006 – present: Ad hoc reviewer for Science, Nature Immunology, Cell Metabolism, Journal of Experimental Medicine, Journal of Clinical Investigation, PNAS, Nature Communications, Science Advances, Advanced Science, Nature Nanotechnology, Cell Reports, eLife, Cancer Research, Clinical Cancer Research, Leukemia, Journal of Immunology, Journal for ImmunoTherapy of Cancer, and JBC.